Literature DB >> 22308284

Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.

Leonie I Kroeze, Gorica Nikoloski, Pedro da Silva-Coelho, Patricia van Hoogen, Ellen Stevens-Linders, Roland P Kuiper, Susanne Schnittger, Torsten Haferlach, Heike L Pahl, Bert A van der Reijden, Joop H Jansen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22308284     DOI： 10.1182/blood-2011-07-365213

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.

Authors:  Vivien Schäfer; Jana Ernst; Jenny Rinke; Nils Winkelmann; James F Beck; Andreas Hochhaus; Bernd Gruhn; Thomas Ernst
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-11       Impact factor: 4.553

Review 2.  Epigenetic regulators and their impact on therapy in acute myeloid leukemia.

Authors:  Friederike Pastore; Ross L Levine
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

3.  Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies.

Authors:  Lizhi Tang; Tianyuan Xiong; Qingyi Jia; Qing He; Xiang Tong; Yuanling Peng; Jiani Shen; Jiqiao Yang; Yonggang Zhang
Journal:  Tumour Biol       Date:  2014-01-12

Review 4.  Chromatin modifiers and the promise of epigenetic therapy in acute leukemia.

Authors:  S M Greenblatt; S D Nimer
Journal:  Leukemia       Date:  2014-03-10       Impact factor: 11.528

Review 5.  Epigenetics in the hematologic malignancies.

Authors:  Chun Yew Fong; Jessica Morison; Mark A Dawson
Journal:  Haematologica       Date:  2014-12       Impact factor: 9.941

Review 6.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

7.  Epigenetic therapy of hematological malignancies: where are we now?

Authors:  Relja Popovic; Mrinal Y Shah; Jonathan D Licht
Journal:  Ther Adv Hematol       Date:  2013-04

Review 8.  miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.

Authors:  Nicola Amodio; Marco Rossi; Lavinia Raimondi; Maria Rita Pitari; Cirino Botta; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2015-05-30

Review 9.  Epigenetics of hematopoiesis and hematological malignancies.

Authors:  Deqing Hu; Ali Shilatifard
Journal:  Genes Dev       Date:  2016-09-15       Impact factor: 11.361

10.  Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.

Authors:  Ling Li; Hailong Zhang; Man Zhang; Mengxi Zhao; Lijian Feng; Xiao Luo; Zhenting Gao; Ying Huang; Ophelia Ardayfio; Ji-Hu Zhang; Ying Lin; Hong Fan; Yuan Mi; Guobin Li; Lei Liu; Leying Feng; Fangjun Luo; Lin Teng; Wei Qi; Johannes Ottl; Andreas Lingel; Dirksen E Bussiere; Zhengtian Yu; Peter Atadja; Chris Lu; En Li; Justin Gu; Kehao Zhao
Journal:  PLoS One       Date:  2017-01-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.